Despite the clear therapeutic promise of anti-EGFR therapies in the preclinical setting, with agents such as gefitinib potently inhibiting growth of a range of human cancer cell lines that express a functional EGFR, there is increasing evidence – from both preclinical and clinical studies – of primary/de novo and acquired resistance to these inhibitors [11-13]. Here, EGFR is linked to cancer.